{"doi":"10.1002/pbc.30467","title":"Minimal residual disease predicts outcomes in <i>KMT2A</i>‐rearranged but not <i>KMT2A</i>‐germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631","abstract":"We measured minimal residual disease (MRD) by multiparameter flow cytometry at three time points (TP) in 117 infants with KMT2A (lysine [K]-specific methyltransferase 2A)-rearranged and 58 with KMT2A-germline acute lymphoblastic leukemia (ALL) on Children's Oncology Group AALL0631 study. For KMT2A-rearranged patients, 3-year event-free survival (EFS) by MRD-positive (≥0.01%) versus MRD-negative (<0.01%) was: TP1: 25% (±6%) versus 49% (±7%; p = .0009); TP2: 21% (±8%) versus 47% (±7%; p < .0001); and TP3: 22% (±14%) versus 51% (±6%; p = .0178). For KMT2A-germline patients, 3-year EFS was: TP1: 88% (±12%) versus 87% (±5%; p = .73); TP2: 100% versus 88% (±5%; p = .24); and TP3: 100% versus 87% (±5%; p = .53). MRD was a strong independent outcome predictor in KMT2A-rearranged, but not KMT2A-germline infant ALL.","journal":"Pediatric Blood & Cancer","year":2023,"id":388312,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.886,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":381791,"name":"John A. Kairalla","orcid":"0009-0005-2430-2921","position":1,"is_corresponding":false},{"id":905032,"name":"ZoAnn E. Dreyer","orcid":"0000-0001-5341-6171","position":2,"is_corresponding":false},{"id":295289,"name":"Andrew J. Carroll","orcid":"0000-0001-9844-730X","position":3,"is_corresponding":false},{"id":252809,"name":"Nyla A. Heerema","orcid":null,"position":4,"is_corresponding":false},{"id":355165,"name":"Meenakshi Devidas","orcid":"0000-0002-1099-3478","position":5,"is_corresponding":false},{"id":247453,"name":"William L. Carroll","orcid":"0000-0003-1550-4167","position":6,"is_corresponding":false},{"id":271728,"name":"Elizabeth A. Raetz","orcid":"0000-0002-8547-1658","position":7,"is_corresponding":false},{"id":301504,"name":"Mignon L. Loh","orcid":"0000-0003-4099-4700","position":8,"is_corresponding":false},{"id":301503,"name":"Stephen P. Hunger","orcid":"0000-0002-5492-3957","position":9,"is_corresponding":false},{"id":357126,"name":"Michael J. Borowitz","orcid":null,"position":10,"is_corresponding":false},{"id":469159,"name":"Cindy Wang","orcid":"0000-0001-5372-2371","position":11,"is_corresponding":false},{"id":263215,"name":"Erin Guest","orcid":"0000-0003-2482-5608","position":12,"is_corresponding":false},{"id":339470,"name":"Patrick A. Brown","orcid":"0000-0002-8653-1069","position":13,"is_corresponding":false},{"id":345406,"name":"Kelly Faulk","orcid":"0000-0002-8240-7490","position":0,"is_corresponding":true}],"reference_count":14,"raw_metadata":null,"created_at":"2026-07-19T01:18:13.977537Z","pmid":"37259259","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}